Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health through a private placement. Cocrystal sold 5,474,053 shares of its common stock to OPKO at $0.9134 per share, with no warrants or other derivative securities included. The company expects to report topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026. OPKO Health Chairman and CEO Dr. Phillip Frost said the additional investment reflects continued conviction in Cocrystal's science and its path forward.
Cocrystal Pharma IncSecures $5M private placement from OPKO Health, providing funding.
Opko Health IncOPKO Health increases investment in Cocrystal, reflecting conviction in its science.